Ποια είναι η τιμή για Ercros, S.A. (ECR)

Η τιμή για Ercros, S.A. (ECR) είναι $4.15

Ποια είναι η κεφαλαιοποίηση αγοράς για Ercros, S.A. (ECR)

Η κεφαλαιοποίηση αγοράς για Ercros, S.A. (ECR) είναι $379.06M

Ercros, S.A. (ECR) Τιμή και Κεφαλαιοποίηση Αγοράς

Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.

Η τιμή για ECR	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$58,257.05 $379.06M	NVDA	$5.327T	+1,405,170.16%
$50,799.10 $379.06M	AAPL	$4.645T	+1,225,270.17%
$44,514.76 $379.06M	GOOG	$4.070T	+1,073,680.06%
$41,390.39 $379.06M	MSFT	$3.785T	+998,314.45%
$30,514.42 $379.06M	AMZN	$2.790T	+735,965.51%

Η τιμή για ECR

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$58,257.05 $379.06M